Clinical Trial Details
| Trial ID: | L6545 |
| Source ID: | NCT00299871 |
| Associated Drug: | Lixisenatide (Ave0010) |
| Title: | Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: LIXISENATIDE (AVE0010) |
| Outcome Measures: | Primary: HbA1c levels at baseline and endpoint (at 13 weeks). | Secondary: Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon. |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 542 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2006-02 |
| Completion Date: | 2007-08 |
| Results First Posted: | |
| Last Update Posted: | 2014-01-28 |
| Locations: | Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Kiev, Ukraine |
| URL: | https://clinicaltrials.gov/show/NCT00299871 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|